Immix Biopharma

Yahoo Finance • 10 days ago

Immix Biopharma Prices $150 Million Underwritten Offering To Advance NXC-201 Program

(RTTNews) - Immix Biopharma, Inc. (IMMX) announced that it has priced a $150 million underwritten registered offering of its common stock. Offering details The offering includes 16,778,524 shares of its common stock priced at $8.94 per s... Full story

Yahoo Finance • 10 days ago

Immix Biopharma Soars On 95% Complete Response Rate In Interim Data From NEXICART-2 Trial Of NXC-201

(RTTNews) - Immix Biopharma, Inc. (IMMX) announced that it has achieved a complete response rate CR of 95% in the interim data of the NEXICART-2 trial evaluating NXC-201 in the treatment of relapsed/refractory AL Amyloidosis. Following th... Full story

Yahoo Finance • 10 days ago

Immix rises after mid-stage trial data for AL amyloidosis therapy

[Green arrow pointing up and a dollar sign] Immix Biopharma (IMMX [https://seekingalpha.com/symbol/IMMX]) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL amyloidosis, a rare disease characteri... Full story

Yahoo Finance • 10 days ago

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

–    Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)  – –   CR rate now 95% (19 of 20 patients)   – –    All CRs reached within 1 year of follow-up post-dosing    – –    No relapses to-date... Full story

Yahoo Finance • 21 days ago

Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones

​Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy right now. On May 7, Lexicon Pharmaceuticals reported Q1 2026 revenue of $21.1 million, a significant increase from $1.3 million in the prior y... Full story

Yahoo Finance • 26 days ago

Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?

Immix Biopharma Inc. (NASDAQ:IMMX) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Immix Biopharma completed enrollment for its NEXICART-2 Phase 2 clinical trial, a key step toward seeking regula... Full story

Yahoo Finance • 2 months ago

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medical Officer, formerly of Merck and Joh... Full story

Yahoo Finance • 6 months ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in rela... Full story

Yahoo Finance • 6 months ago

Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026

(RTTNews) - Shares of Immix Biopharma Inc. (IMMX) are up nearly 20% at $6.65 in pre-market trade, following presentation of positive results of phase 2 portion of its NEXICART-2 trial in relapsed/refractory AL Amyloidosis at the American S... Full story

Yahoo Finance • 6 months ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered of... Full story

Yahoo Finance • 6 months ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potential... Full story

Yahoo Finance • 7 months ago

Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch

* Immix Biopharma (IMMX [https://seekingalpha.com/symbol/IMMX])has appointed Michael Grabow as Chief Commercial Officer to drive all aspects of commercialization and launch for NXC-201 in relapsed/refractory AL Amyloidosis. * Prior to... Full story

Yahoo Finance • 7 months ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial veteran Mr. Grabow to lead Immix’s... Full story

Yahoo Finance • 7 months ago

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

- Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today a... Full story

Yahoo Finance • 8 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutiona... Full story

Yahoo Finance • 8 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at... Full story

Yahoo Finance • 8 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases,... Full story

Yahoo Finance • 8 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis – Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company... Full story

Yahoo Finance • 9 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-st... Full story

Yahoo Finance • 9 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, t... Full story